Were you or a loved one diagnosed with cancer after taking Zantac?
On September 13, 2019, the U.S. Food and Drug Administration (FDA) released a statement alerting patients and health care professionals about the discovery of the presence of a contaminant N-nitrosodimethylamine (NDMA) in Zantac (ranitidine). Exposure to Zantac and its active ingredient, ranitidine, can lead to an increased risk of developing cancer through NDMA exposure. In response, stores have removed all generic versions of ranitidine and Zantac off their shelves and the drug Zantac has been recalled.
Cancers Zantac has been linked to:
- Brain Cancer
- Bladder Cancer
- Colonrectal/Small Intestine Cancer
- Esophageal Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Pancreatic Cancer
- Testicular Cancer